Copyright
©The Author(s) 2024.
World J Gastroenterol. Mar 7, 2024; 30(9): 1043-1072
Published online Mar 7, 2024. doi: 10.3748/wjg.v30.i9.1043
Published online Mar 7, 2024. doi: 10.3748/wjg.v30.i9.1043
Medications | Actions | Dose (kg/d) | Adverse effects |
Ursodeoxycholic acid | Choleretic, stimulates bile flow | 10-20 mg | Vomiting, diarrhea, and abdominal pain |
Cholestyramine | Bile acid-binding resins | 0.25-0.5 g | Vomiting, diarrhea, and poor palatability |
Rifampicin | Pregnane X receptor agonist increases the metabolism of pruritogenic substances | 5-10 mg | Hepatitis, thrombocytopenia, hemolytic anemia, and red discoloration of bodily fluid (sweat, tears) |
Phenobarbital | Choleretic enhancement of glucuronyl transferase activity | 5-10 mg | Central nervous system depression and vomiting |
Naltrexone | Opioid receptor antagonist | 0.25-0.5 mg | Opioid withdrawal-like reactions, abdominal pain, and irritability |
Maralixibat | Ileal bile salt transporter | 380 μg | Diarrhea, abdominal pain, and rash |
Ondansetron | Serotonin (5-HT3) receptor antagonist | 0.1-0.2 mg | Dizziness, constipation |
Hydroxyzine | Antihistamine | 2 mg | Rash, drowsiness, and dry mouth |
Diphenhydramine | Antihistamine | 5 mg/kg/d | Drowsiness, constipation, and nausea |
- Citation: Eiamkulbutr S, Tubjareon C, Sanpavat A, Phewplung T, Srisan N, Sintusek P. Diseases of bile duct in children. World J Gastroenterol 2024; 30(9): 1043-1072
- URL: https://www.wjgnet.com/1007-9327/full/v30/i9/1043.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i9.1043